As we all know, the fundamental principle [9] behind the use of PD1/PD‐L1 inhibitors in cancer treatment is that tumor cells evade immune surveillance by overexpressing PD‐L1, which then binds to PD1 on cytotoxic T cells, leading these T cells to recognize tumor cells as “normal.” By blocking the interaction between PD1 on cytotoxic T cells and PD‐L1 on tumor cells, PD1/PD‐L1 inhibitors enable cytotoxic T cells to continue recognizing and killing tumor cells. This evidence concerns the gene CD274 and neoplasm.